RT Journal Article
T1 The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency
A1 De Pablo Moreno, Juan Andrés
A1 Miguel Batuecas, Andrea
A1 De Sancha, María
A1 Liras Martín, Antonio
AB Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.
PB MDPI
SN 1661-6596
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/110752
UL https://hdl.handle.net/20.500.14352/110752
LA eng
NO De Pablo-Moreno, J. A., Miguel-Batuecas, A., de Sancha, M., & Liras, A. (2023). The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency [Review of The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency]. International Journal of Molecular Sciences, 24(7). MDPI. https://doi.org/10.3390/IJMS24076243
NO This research was funded by the Association for Research and Cure of Factor V deficiency (ASDEFAV), grant number ASDEFAV/2021-23, and by Complutense University of Madrid and Banco Santander, grant number CT63/19-CT64/19.
NO Asociación para la Investigación y Cura del Déficit de Factor V (ASDEFAV)
NO Universidad Complutense de Madrid
NO Banco Santander
DS Docta Complutense
RD 7 abr 2025